Dear Experimental Center,

 In relation to the request to subject the CRA to procedures aimed at excluding coronavirus infection (SARS-CoV-2) before entering the premises of the clinical center to carry out a monitoring visit, such as CRO associated with AICRO (Italian Contract Research Organization)  the official position of AICRO available [here](http://www.aicro.it/en/news-2020/) and we wish to point out that the writer:

 - fulfills, as an employer, the legal obligations in force regarding the contrast and containment of the diffusion of CoViD-19 in the workplace and adopts specific and formal protocols for this purpose;

 - is required to monitor the health of its employees and, in the event of suspected contagion risk, to put in place all the procedures that also limit the potential spread of the contagion;

 - is required to provide its employees with adequate and sufficient Personal Protective Equipment to protect health and aimed at preventing contagion even during travel.

 Consequently, we do not believe that CRAs must undergo these tests "on demand" and perhaps frequently, in different centers and with different methods, on which there is still uncertainty on the reliability and there is no evidence of how the results and sensitive data of the CRA.

 Recalling that the need to periodically visit the centers is a regulatory requirement (sanctioned by GCP-ICH DM 15/7/97), as well as a way to guarantee the quality of the trials and patient safety, in the interest of the Experimental Center itself  , we believe that the precautions already implemented by the writer CRO associated with AICRO are sufficient, and we invite you to allow access to our CRAs.